Eneida Harrison

Preview of our paper on safety and efficacy of catheter directed thrombolysis in the elderly. #templelung #TempleMed @ParthRali @PatelMaulin17 @rtg03 @ramialashram @RiyazBashir @GerardCriner bmjopenrespres.bmj.com/content/8/1/e0…

@GinnyMarmolejos It was a pleasure working with you Ginny!! Good luck on your next endeavor as an awesome attending!!!

Quick summary of some of the therapeutic options being studied Therapeutic options for the 2019 novel coronavirus (2019-nCoV) nature.com/articles/d4157…

@bobby_marron @ParthRali @Rami_MS @PatelMaulin17 @TempleLung Thank you Bobby!! 😊

@eneida_harrison @ParthRali @Rami_MS @PatelMaulin17 @TempleLung And you published another review with Dr Kim too? Congrats

Our first Blue Journal Publication!! “Pulmonary Embolism: Controversies in Therapeutic Management” Thank you to @ParthRali for being such a wonderful mentor. @Rami_MS @PatelMaulin17 @TempleLung

@bobby_marron @ParthRali @Rami_MS @PatelMaulin17 @TempleLung Yeah, we just found out a few hours later.

@eneida_harrison @ParthRali @Rami_MS @PatelMaulin17 @TempleLung Did this get published since we spoke this morning?

Which long-acting pharmacotherapeutic option is best for patients with moderate or severe #COPD? Read this recently published article by Drs. @VictorKimMD and @Eneida79601391 for their assessment: bit.ly/2OxbqdM

New study led by @TempleLung and published in #AJRCCM: minimally invasive #Spiration valve treatment for severe emphysema demonstrates significant improvement in outcomes. bit.ly/2ZlV9f4

@TempleLung @PERTConsortium thank you everyone for support and opportunity!!! It’s an amazing conference.

#TempleLung #ats_pc